NEWTON, Mass. and HAGERSTOWN, Md., April 24, 2018 -- MariMed Inc. (OTCQB:MRMD) and Kind Therapeutics USA today debuted Nature’s Heritage Cannabis®, a branded line of organic marijuana products that is “Rooted in Excellence.” MariMed has sought out the finest seed lineages in the world and developed them into “The best cannabis Mother Earth has to offer®.” MariMed selected only the best strains that perfectly embody the rich heritage and subtle nuances of their origins. Nature’s Heritage Cannabis products are produced from genetically pure strains, now 100% organically grown at the Kind Therapeutics USA’s state licensed cultivation facility in Hagerstown, Maryland. This facility is managed by MariMed Inc.
Nature’s Heritage Cannabis branded products include:
- Flower – bulk and prepackaged. Each natural bud is coated in crystal-like resin rich with THC and CBD.
- Concentrates – CO2 wax, live resin, shatter, CO2 terp sauce and budder skillfully made from choice strains, capturing the smell, taste and effects of the original plant.
- Vape Pens – cartridges and mini pens, and disposable pens contain premium oil that has been extracted from the world’s finest cannabis plants, preserving the aroma, flavor and effect of the original plant.
- Extracts – tinctures, capsules, topicals and RSO syringes. Famous for its cancer wonders, pure RSO oil is 100% pure premium cannabis oil with all the cannabinoids that offer the same beneficial effects as the original plant in easy to use products.
“Nature’s Heritage Cannabis is all about experiencing the rich heritage and medicinal benefits of the finest lines of cannabis from every corner of the world,” stated Tim Shaw, MariMed COO who heads up Product Development. “’Each product is stamped with ‘Rooted in Excellence,’ which exemplifies how we have gone back to the basics of organic farming with these heirloom lines and carefully manage every step of the process from seed to sale. This ensures that patients can enjoy marijuana’s full potential at its very best, purest state - free of pesticides and contaminants - as it was centuries ago, yet in convenient products that fit today’s lifestyles and meet their medical needs.”
“The Nature’s Heritage Cannabis brand has an adventurous ‘Old World’ treasure hunt look with antiqued parchment packaging and maps showing the origin and history of each of the treasured cannabis strains,” noted Tim Tennant, MariMed Chief Marketing Officer. “We really want patients to explore the effectiveness of the Nature’s Heritage strains in treating their symptoms and develop a true appreciation for how their power has been harnessed in convenient, ready to use products.”
Kind Therapeutics USA grows Nature’s Heritage Cannabis Sativa, Indica and Hybrid strains in its cultivation facility in Hagerstown, Maryland. Its adjoining production facility manufactures products in THC and CBD formulations and distributes them to dispensaries throughout Maryland. MariMed Inc. developed and provides management oversight of this facility including its product selection and all its operations. For more information on Nature’s Heritage at Kind, visit https://kindtherapeuticsusa.com/natures-heritage/
Search MariMed and post on social media with the hash tag #MedicatedByMarimed:
Twitter: @MariMedInc
Facebook: @MariMedInc
Instagram: MariMedInc
YouTube: MariMedInc
About MariMed Inc.:
MariMed designs, develops, finances, and optimizes the success of medical cannabis cultivation, production, and dispensary facilities through its validated management. MariMed's team has developed or is in the process of developing state-of-the art regulatory-compliant facilities in DE, IL, NV, MD, MA and RI. These facilities are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. In addition, MariMed is on the forefront of precision dosed branded products for the treatment of specific medical symptoms. MariMed currently distributes its branded products in select states and is expanding licensing and distribution to numerous additional states encompassing thousands of dispensaries. MariMed Inc. is one of the 17 top-performing public cannabis companies in the U.S. tracked on the U.S. Marijuana Index, (www.marijuanaindex.com) and CannabIndex. For additional information, visit www.MarimedAdvisors.com
MariMed Contacts:
Business Development
Jon Levine, CFO, MariMed, Inc.
+1 844-244-0200
Investor Relations
Tyler Troup, Circadian Group
[email protected]
+1 (866) 950 8300
Media Relations
Julie Shepherd, Accentuate PR
[email protected]
+1 847-275-3643
Forward Looking Statements:
This release contains certain forward-looking statements and information relating to MariMed Inc., that is based on the beliefs of MariMed Inc. management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the economic environment and changes in the legal status of cannabis. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned," "estimated," "preparing," “seek,” "potential," "expected" or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites of any other party referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.
A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/e915273c-937b-4f55-96e9-1d01e4904481


Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan
Tesla Raises Cybertruck Prices by $5,000 in US
Bathla Group Hires Administrators as Australia Housing Slump Deepens
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny
Trump Buys SpaceX Shares After Record IPO
Nvidia Options Price in $280 Billion Earnings Swing
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing
Meta, U.S. States Discuss Settlement in Teen Addiction Trial
Yindjibarndi Appeals Fortescue Mining Compensation Ruling
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition
Trump Administration Plans New Drug Pricing Deals With Biotech Firms
Mercer International Stock Surges 45% on C$20 Million Canada Funding
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 



